$MRNA $VXRT $SRNE | Breaking News: Vaxart Gets FDA Clearance for Oral COVID-19 Vaccine Candidate Phase 1 Trial. The trial will enroll adults ages 18 to 55 years old and determine the safety and reactogenicity of two-doses of the vaccine. It will also evaluate immunogenicity, duration of immune response and occurrence of symptomatic COVID-19, according to the company. The biotechnology company also said it is conducting a SARS-CoV-2 challenge study in hamsters which will yield efficacy data and insights into the oral tablet vaccine's optimal dose regimen. It expects to obtain data from the study in mid-October.